PCA3 is significantly elevated in patients with prostate cancer, and several available studies show the utility of PCA3, as a urinary biomarker, for the diagnosis of early prostate cancer with reasonable specificity and sensitivity [61,62]. This evidence concerns the gene PCA3 and prostate carcinoma.